Keywords: repligen, rpf4, massachusetts-based, corp, established, partnership, support
REPLIGEN'S rPF4
Article | 16 March 1992
Massachusetts-based Repligen Corp has established a partnership to support the $45 million cost of the development of its recombinant platelet factor 4 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
